BioSpace News Archive

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will effect a 1-for-25 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on October 26, 2022.

IQVIA Holdings Inc., announced that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Credit Suisse Annual Healthcare Conference in Rancho Palos Verdes on Tuesday, November 8, 2022 at 12:10 p.m. ET.

Stevanato Group S.p.A. announced that it will issue financial results for the third quarter of 2022 on Tuesday, November 8, 2022, at 6:30 a.m. Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. on Tuesday, November 8, 2022 to discuss financial results for the third quarter.

Medpace Holdings, Inc. announced financial results for the third quarter ended September 30, 2022.

Zivo Bioscience, Inc. announced plans to create ZIVOLife LLC, a newly formed wholly-owned subsidiary, to streamline the Company’s corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generating revenue from the Company’s proprietary algae biomass.

NyxoahSA announced that Raymond Cohen resigned as member of the board of directors of the Company effective October 18, 2022.

SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced that it will report financial results for the third quarter 2022 before market open on Monday, November 14, 2022.

Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it will host a R&D update call on Monday, October 31, 2022 at 8:00 am ET on the alvelestat (MPH966) program for alpha-1-antitrypsin deficiency (AATD).

Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time.

Denali Therapeutics Inc. announced the closing of its upsized underwritten public offering of 11,933,962 shares of its common stock at a price to the public of $26.50 per share, which includes the exercise in full by the underwriters of their option to purchase additional shares.